ERBB2 and breast carcinoma: It is indicated in the adjuvant treatment of patients with HER2-positive early breast cancer with residual invasive disease after the administration of a trastuzumab- and taxane-based neoadjuvant regimen and in the advanced setting, for patients with HER2-positive MBC who previously received trastuzumab and a taxane, separately or in combination.